Union Minister of Commerce and Industry, Piyush Goyal, recently engaged with key stakeholders from India’s pharmaceutical ecosystem in a meeting aimed at strengthening industry growth and advancing regulatory reforms. The discussion centered on India’s global pharma competitiveness, innovation, data protection frameworks, investment commitments, and scaling up manufacturing within the country.

Minister Goyal emphasized the Modi Government’s commitment to nurturing a future-ready, innovation-led pharmaceutical sector that can boost competitiveness, attract quality investments, and deliver affordable, world-class healthcare solutions. “Had an engaging interaction with key stakeholders from India’s pharma ecosystem, focusing on strengthening our regulatory frameworks and accelerating growth,” Goyal stated in a social media post.

The meeting comes as the global pharmaceutical industry faces uncertainty over proposed US tariffs on pharmaceutical imports. US President Donald Trump had announced a plan to impose a 100 percent tariff on branded and patented pharmaceutical products starting October 1, 2025, unless companies set up production facilities in the United States. However, the implementation of these measures remains pending.

Indian industry representatives, however, are optimistic that the tariff move will not significantly impact Indian pharmaceutical exports. Sudarshan Jain, General Secretary of the Indian Pharmaceutical Alliance (IPA), noted that India’s exports to the US primarily consist of generic drugs and active pharmaceutical ingredients (APIs), which are not covered under the announced tariffs. Experts believe India’s strong position in the generics market provides resilience against global trade disruptions.

Government records show that the US remains India’s largest pharma export destination, accounting for over 31% of total exports and 47% of generic drug exports. In September 2025, India’s pharmaceutical exports to the US reached $2.62 billion, underscoring the sector’s robust international presence.

Industry leaders and policymakers remain focused on supporting long-term growth through sustained innovation, increased manufacturing capacity, and ongoing regulatory efficiency, positioning India as a global leader in pharmaceuticals.